Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants
Phase 1
Completed
- Conditions
- Fibrostenotic Crohn’s disease
- Registration Number
- 2023-504460-41-00
- Lead Sponsor
- Agomab Spain S.L.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ended
- Sex
- Not specified
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular targets of AGMB-129 in fibrostenotic Crohn’s disease pathogenesis?
How does AGMB-129 compare to standard-of-care therapies for fibrostenotic Crohn’s disease in clinical trials?
Which biomarkers could predict AGMB-129 efficacy in fibrostenotic Crohn’s disease patients?
What are the known adverse events associated with AGMB-129 in early-phase trials for Crohn’s disease?
Are there combination therapies involving AGMB-129 being explored for fibrostenotic Crohn’s disease treatment?
Trial Locations
- Locations (1)
SGS Belgium
🇧🇪Edegem, Belgium
SGS Belgium🇧🇪Edegem, BelgiumFrédéric VanhoutteSite contact032172560frederic.vanhoutte@sgs.com